Sanofi and Cambridge, Massachusetts-based Revolution Medicines have announced a cooperation agreement aimed at developing and, subsequently, marketing Revolution’s technology, based on the inhibition of the cellular enzyme SHP2, for patients with non-small lung cancer. Its most-advanced-stage investigational drug is RMC-4360. As part of the agreement, Sanofi will purchase all Revolution Medicines’ marketing rights to drugs developed with the technology mentioned before, and the companies will equally share the generated profits. Moreover, thanks to the agreement, Revolution Medicines will receive royalties on sales generated by Sanofi with the developed drugs. Besides, the company will be eligible for an upfront $50m payment, plus payments up to $500m, upon reaching precise milestones.
(Source: Revolution Medicines)